From the company's own site, we can see this pharma brand has a diversified portfolio of therapies across multiple clinical ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

“The development of Muse, a result of our ongoing collaboration with OpenAI and Formation Bio, represents another proof point ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

An eczema drug jointly developed by pharmaceutical companies Regeneron and Sanofi continues to stand above all comers when it ...

Brad Lightcap, COO, OpenAI "We believe AI can accelerate drug development, bringing new treatments to patients more quickly. This first product from our collaboration with Sanofi and Formation Bio is ...

Key non-cystic fibrosis bronchiectasis companies such as Zambon SpA, Insmed, Armata Pharmaceuticals, Verona Pharma, Haisco Pharmaceutical Group, Infex therapeutics, Boehringer Ingelheim, Regeneron ...